Test sputum-guided care to reduce cough in lung scarring
Part of Lungs & breathing clinical trials.
This study uses analysis of mucus (sputum) to guide treatment with the goal of reducing long-lasting cough in adults with interstitial lung disease (ILD). You may be asked to provide sputum samples and may receive treatment decisions based on those results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can give written consent
- You have ILD (lung scarring) such as IPF, chronic hypersensitivity pneumonitis, CTD-ILD, or pneumoconiosis
- Your cough has lasted daily for at least 8 weeks
- You can produce an adequate sputum sample (sometimes using a breathing treatment to help you cough it up)
- You do not have certain ILD types, like systemic sclerosis–related ILD or sarcoidosis
- Your cough is not from another clear cause (like reflux, certain blood pressure medicines, or a recent viral illness)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a non-medication cough-control program for people who have lung scarring (interstitial lung disease) and a cough lasting more than 8 weeks. It may help you control coughing better without adding new medicines.
This trial is testing a telehealth program (using phone calls or video meetings) to help people with interstitial lung disease manage chronic cough. If you join, you'll get guidance and support to improve your cough symptoms and quality of life.
This Phase 2 study tests whether two different doses of duloxetine and amitriptyline can reduce coughing caused by interstitial lung disease (ILD). If you have had a long-lasting ILD-related cough despite stable ILD treatment, this trial may help find a better way to control your cough.
This study tests two cough-relief medicines, gabapentin and benzonatate, against usual care in people with interstitial lung disease (lung scarring) who have had a chronic cough for at least 8 weeks. It aims to see which option works better and is safer.
This study aims to improve how doctors diagnose and classify lung conditions that affect both the air sacs and airways, such as COPD and pulmonary fibrosis. By participating, you may help advance medical knowledge and better understand your own condition.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Hear when a new ILD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.